报价延迟最少15分钟:2026/07/11 15:10 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.57 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-11.84/-14.49
|
|
企业价值
35.58M
|
| 资产负债 |
|
每股账面净值
3.66
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02. |
